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Abstract: Cocaine opens the blood-brain barrier by deregulating transcription of target genes. Here we show that cocaine 
at blood concentrations in drug abusers disrupts endothelial cell junctions in parallel with signaling by phosphorylation of 
extracellular signal-regulated kinase, myristoylated alanine-rich C kinase and myosin light chain. Cocaine effects may be 
important in vivo since the neurons of drug abusing patients with HIV-1 associated dementia displayed gp120, p24 and 
Nef. 
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INTRODUCTION 
  Although the incidence of HIV-1-associated dementia 
(HAD) has been decreasing since the advent of HAART, the 
prevalence of chronic neurological disease associated with 
HIV-1 has been increasing. Drug abuse may be an important 
risk factor in chronic neurological complications of HIV-1 
infection. There are compelling reasons why cocaine abuse 
might increase the risk of HIV-1 infection of the brain [1]. 
Cocaine opens the blood-brain barrier to HIV-1 [2] by re-
modeling brain microvascular endothelial cells (BMVEC’s) 
and disrupting virus macropinocytosis and degradation in 
lysosomes [3]. 
We have shown that HIV-1 may use two different mecha-
nisms to penetrate the blood-brain barrier (BBB): a “Trojan-
horse” transport into the brain in monocytes and lymphocytes 
[4, 5] or macropinocytosis of cell-free virus in BMVEC’s [6]. 
In this study, we examined the concentrations of cocaine   
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necessary for cell signaling and disruption of BMVEC’s in 
order to clarify the presence of HIV-1 antigens in neurons of 
drug abusing patients with HAD. 
METHODS 
Brain Microvascular Endothelial Cells 
  Human BMVEC’s were isolated from temporal lobe tis-
sues removed during neurosurgical procedures and cultured 
as previously described [6]. Confluent monolayers of 
BMVEC’s were prepared by seeding 100,000 cells into each 
well of an 8- well tissue culture- treated slides (Becton Dick-
inson Falcon, Bedford, Massachusetts, USA) containing 0.5 
ml of DME/F12 (InVitrogen, Carlsbad, California, USA) 
with 10% fetal calf serum and incubating cell cultures for 4-
6 days to confluence. To study cocaine’s signaling, cocaine 
(Research Triangle Institute, North Carolina, USA) (1:100 
dilution of freshly diluted 100x stock in DME/F12) was 
added to achieve the indicated concentration in the medium. 
Brain Tissues 
  The National Neurological AIDS Bank at UCLA pro-
vided formalin-fixed, paraffin-embedded frontal lobe and 
hippocampal tissues of five HIV-1-positive patients (four HIV–1 Antigens in Neurons of Cocaine-Abusing Patients  The Open Virology Journal, 2008, Volume 2    25 
patients had a history of drug abuse including cocaine with 
additional alcohol and opiate abuse in some; the last patient 
had no history of drug abuse) and two amyotrophic lateral 
sclerosis (ALS) brain tissues. The autopsy interval ranged 
between 5 to 6 h except that of one ALS patient, which was 
22 h. The Manhattan HIV Brain Bank provided brain tissue 
of a patient with minor cognitive impairment who had brain 
lymphoma and was taking medically prescribed opiates. The 
UCLA Brain Bank provided HIV-1-negative control tissues 
(amyotrophic lateral sclerosis) and two brain tissues of HAD 
patients who died in the late 1980’s. The protocol was re-
viewed and approved by the UCLA Institutional Review 
Board. 
Immunohistochemistry (IHC) 
  Tissues were subjected to antigen retrieval solution 
(DAKO) in a steamer for 20 min and were treated with Dual 
endogenous enzyme block and Protein block (DAKO, 
Carpinteria, California, USA). IHC was performed by the 
Envision technique (with primary rabbit and mouse antibod-
ies) or the LSAB 2 technique (with primary goat antibodies) 
(DAKO) as previously described [7]. The primary antibodies 
were anti-gp120, anti-p24, anti-Nef (all three, which are de-
scribed below, were provided by the AIDS Research and 
Reference Reagent Program, NIH, Bethesda, USA), anti-
NeuN (Chemicon, Temecula, California, USA), anti-CD68 
and anti-GFAP (DAKO). 
  Two gp120 monoclonal antibodies were used: ID6 [8] 
and 670-30D [9]. The murine ID6 monoclonal antibody was 
generated after immunization of a mouse with a recombinant 
gp160 immunogen. Subsequent analysis using screening of 
phage display libraries with ID6 indicated that the epitope 
was contained within amino acids 86-100 of the highly con-
served C1 region of gp120. One of the phage mimotopes 
generated by screening with ID6 (designated phage 3.3) 
bound to ID6 with a high affinity. Two IHC studies were 
done using ID6 absorbed with the relevant gp120 epitope. In 
the first, equal volumes of the ID6 antibody (1:100) and re-
combinant gp120JR-FL (250 ng/μL) were incubated at 37
o C 
for 3 hrs and, after ultracentrifugation, the top half of the 
suspension was used in IHC. Recombinant gp120 was pro-
duced in Chinese hamster ovary cells as described [10]. In 
the second study, ID6 antibody (1:100) was incubated with 
phage 2.13 (negative phage mimotope) or phage 3.3 (posi-
tive phage mimotope) [8] (each at 1:800) and processed as 
above. 
  Gag was detected using monoclonal anti-p25/24 (ISF2) 
and anti-p24 (AG 3.0); Nef was stained using anti-HIV-1 
IIIB Nef (AE6) and anti-Nef (EH1). 
Transmission Electron Microscopy (TEM) 
  BMVEC cultures grown on cover slips in 24-well plastic 
dishes were fixed by immersion according to standard proto-
cols that take into consideration our desire to produce excel-
lent ultrastructural preservation of EC cytoskeletal filaments, 
microtubules, and EC junctional complexes. For this reason, 
we fixed the BMVEC at room temperature (25EC) to avoid 
disruption of EC cytoskeletal components such as microtu-
bules. The fixative contained 2.5-3.0% glutaraldehyde in 0.1 
M sodium cacodylate buffer, pH 7.4 [11]. BMVEC were 
post-fixed with 1% osmium tetroxide, dehydrated in a 
graded series of ethanol, and en bloc stained with uranyl   
 
acetate [12]. The coverslips were infiltrated with liquid ep-
oxy plastic overnight in a desiccator at 25EC. On the next 
day, in liquid plastic, the coverslips were sliced into several 
pieces and flat-embedded with the BMVEC positioned up-
ward then polymerized in a 60EC oven overnight. For TEM 
and HVEM studies, plastic thick- and thin-sections were cut 
with either the Leica Ultracut UCT and Sorvall (MT-1) Ul-
tramicrotomes and stained with lead and uranyl salts, accord-
ing to standard protocols (Hayat, 1981). Thin-sections were 
collected on grids, stained with uranium and lead salts and 
examined with the FEI Morgagni Electron Microscope. 
Western Blot Analysis 
  Confluent monolayers of BMVEC’s were incubated over-
night in serum-free DME/F12 medium and treated with co-
caine as indicated. Cell extracts were prepared by washing cell 
monolayers three times with phosphate buffered saline (PBS), 
scraping the cells into SDS sample buffer (125 mM Tris pH 
6.8, 4% SDS, 10% glycerol, 0.006% bromophenol blue, 2% 2-
mercaptoethanol), then passing them through a 26-gauge nee-
dle. After 5 min of boiling, the protein samples were centri-
fuged for 2 min and separated by sodium dodecyl sulfate-10% 
polyacrylamide gel electrophoresis (SDS-PAGE) [13]; the 
proteins were transferred to nitrocellulose membranes (30 V 
for 18 h or 90 V for 2 h) [14] and incubated with specific anti-
bodies. The antibodies of interest included anti-phospho-
myosin light chain 2 and anti-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (Cell Signaling, Danvers, Massa-
chusetts, USA); anti-phospho-extracellular signal-regulated 
kinases 1 and 2 (Erk1/2) (New England BioLab, Beverly, 
Massachusetts, USA); anti-phosphor-specific myristoylated 
alanine-rich C kinase substrate (MARCKS) (ProteinTech 
Group, Chicago, Illinois, USA); and anti- myosin light chain 
(MLC) (Sigma, St. Louis, Missouri, USA). Immunoreactive 
proteins were detected with enhanced chemiluminescent de-
tection system (ECL) according to the manufacturer's direc-
tions (Amersham, Little Chalfont, UK). The experiments were 
repeated three times. To evaluate the protein loading, the 
membranes were stained with GAPDH or MLC antibody. 
RESULTS 
10
-5 to 10
-7M Cocaine Disrupt Confluent BMVEC’s in 
Parallel with Cell Signaling 
  Cocaine concentrations 10
-5 to 10
-7M disrupted endothe-
lial junctions and produced gaps between BMVEC’s (Fig. 1). 
 Cocaine  concentrations  10
-8M and below had minimal 
effects on BMVEC’s. Benztropine is a therapeutic agent that, 
in addition to binding to the biogenic amine transporters and 
muscarinic receptors, binds with high affinity to a cocaine-
binding site on BMVEC’s [3]. Similarly as cocaine, 10
-5 to 
10
-7M benztropine produced gaps between endothelial cells 
(not shown). 10
-5 to 10
-7M cocaine treatment of BMVEC’s 
induced phosphorylation of Erk 1/2, MARSKC and MLC 
(Fig. 2). Cocaine concentrations10
-8 and below did not con-
sistently induce cell signaling. Benztropine has a higher af-
finity for the cocaine-binding site on BMVEC’s than cocaine 
[3]. Accordingly, stimulation by 10
-6 M benztropine induced 
more prolonged signaling through Erk1/2 and MLC phos-
phorylation in comparison to cocaine (Fig. 2). 26    The Open Virology Journal, 2008, Volume 2  Fiala et al. 
 
Fig. (1). Cocaine disrupts BMVEC junctions. Confluent BMVEC monolayers were treated with the indicated concentration of cocaine for 
1h; the cells were then washed, fixed, stained with phalloidin-ALEXA 594 and photographed by Hamamatsu camera on the Olympus Bmax 
microscope (40x). The arrows indicate gaps between BMVEC’s. HIV–1 Antigens in Neurons of Cocaine-Abusing Patients  The Open Virology Journal, 2008, Volume 2    27 
  Confluent BMVEC monolayers were treated with the 
indicated concentration and time of exposure to cocaine; cell 
extracts were prepared and analyzed by SDS-PAGE with 
antibodies to phospho-Erk 1/2, MARCKS and MLC. Stain-
ing with antibodies to GAPDH and MLC demonstrated equal 
loading. 
Ultrastructural Features of Monocyte Migration Across 
BMVEC’s 
  In the BBB model, monocyte migration was stimulated 
by MCP-1 in the lower chamber. Monocytes migrated be-
tween the endothelial cells, which became thick above each 
pore (Fig. 3A). Monocytes migrated through the pore into 
the brain chamber (Fig. 3B). The rate of monocyte migration 
was increased by cocaine, as previously published [2]. 
(A) 
 
(B) 
 
Fig. (3). Ultrastructural features of monocyte migration through the 
BMVEC model of the blood-brain barrier. (A) Endothelial layer 
becomes thick above the pores through which the monocytes are 
migrating (1,000x section of the BBB model with migrating mono-
cytes). (B) Monocytes migrate between endothelial cells and 
through the pore (TEM, 10,000 x). 
  24-h treatment of BMVEC’s with 10
-6M cocaine pro-
duced robust vacuolization of the endothelial cell cytoplasm 
(Fig. 4 ) and increased monocyte transmigration, as previ-
ously published [15]. 
(a) Control 
 
(b) Cocaine 10
-6 M 
 
Fig. (4). Ultrastructural features of monocyte migration through the 
BMVEC model of the blood-brain barrier. Compared to the un-
treated cells (a), cocaine-treated BMVEC’s (b) display cytoplasmic 
vacuolization (TEM, 10,000 x). 
  As shown above (Fig. 1), cocaine at the concentrations in 
the plasma of cocaine’s addicts (10
–6M to 10
–8M) disrupts 
BBB. We have searched for increased evidence of HIV-1 in 
brain tissues of drug-abusing patients with HAD. 
 
 
Fig. (2). Cocaine and benztropine induce phosphorylation of Erk 1/2, MARCKS and MLC in BMVEC’s. 28    The Open Virology Journal, 2008, Volume 2  Fiala et al. 
Frontal Lobe Neurons of Drug-Using Patients are Posi-
tive for gp120, p24 and Nef 
  To detect viral “foot-prints” in brain tissues, we per-
formed IHC with the monoclonal gp120 antibody ID6 with 
brain tissues of six HAD patients, four with a history of drug 
abuse, one with a history of opiate use for medical reasons, 
and one without any history of drug use. All patients were 
intensively treated until their death with HAART. The neu-
ropathology was remarkable for absence of perivascular in-
filtration by macrophages and lack of gp120 staining of mi-
croglia, which were noted in brain tissues of patients with 
HAD who died in the eighties (Fig. 5). The brain tissues of 
the patient without a history of drug abuse were completely 
negative for gp120 (Table 1). 
  However, the five patients with a history of drug abuse or 
medical use of morphine had expression of gp120 (brown) in 
neurons, as shown by double staining with MAP-2 antibody 
(red) (Fig. 6a), but not in astrocytes (Fig. 6b). 
  To confirm the specificity of gp120 staining with the ID6 
antibody, this antibody was absorbed with the phage 3.3 
mimotope (Fig. 6d), which removed the reactivity, whereas 
absorption with the unrelated phage 2.13 had no effect on the 
staining (Fig. 6c). Absorption of the ID6 antibody with 
gp120 also reduced neuronal staining (not shown).  
  Furthermore, ID6 antibody did not stain neurons of con-
trol patients (e.g., ALS case) and unrelated antibody (CD20) 
did not stain neurons in HAD brain tissues. In addition, neu-
rons in the frontal lobe tissues were positively stained by two 
different p24 (Fig. 7a,b) and two different Nef antibodies 
(Fig. 7c,d). 
 
(a)            ( b) 
 
 
 
 
Fig. (5). Perivascular infiltration by macrophages in HAD brain tissues. (a) Minimal perivascular macrophage infiltration in patient 1 (IHC 
with CD68 antibody). (b) Robust macrophage infiltration of vessels in an AIDS patient dying in late 1980’s. 
 
Table.1. HIV-1  Positive
a and Control
b Patients – Diagnostic
a and Virological
b Data 
 
Neuronal Staining
c 
Subject   Age/Sex   Cocaine  
Abuse  
Other Risk  
Factors  Neuropathological Diagnosis  
gp120  p24 Nef 
HIV 1  46 M  No  Morphine
d  White matter pallor, gliosis  +  +  N.D. 
HIV 2  29 F  Yes  No  Alzheimer type II gliosis   +  +  + 
HIV 3  58 F  Yes  No  N.D.  +  N.D  N.D. 
HIV 4  44 M  Yes  Alcoholism  Alzheimer type II gliosis; HIV encephalitis  +  N.D.  N.D. 
HIV 5  34 F  Yes  No  HIV encephalitis; cryptococcal meningitis  +  +  + 
HIV 6  42 M  No  No  Minimal non-diagnostic abnormalities  –  –  – 
Ctrl 1  69 M  No  No  ALS; Anoxic-ischemic encephalopathy; laminar necrosis in occipital cortex  – –  – 
Ctrl 2  66 M  No  No  ALS  –  N.D.  N.D. 
Ctrl 3   86 F  No  No  No neuropathology  –  N.D.  N.D. 
Ctrl 4  90 F  No  No  No neuropathology  –  N.D.  N.D. 
aAll HIV subjects except #6 had neurocognitive diagnosis of HAD. 
bAll controls were HIV-1 negative. Control 1 and 2 had amyotrophic lateral sclerosis (ALS). 
cPost-mortem frontal lobe and hippocampus. 
dMorphine for pain control. HIV–1 Antigens in Neurons of Cocaine-Abusing Patients  The Open Virology Journal, 2008, Volume 2    29 
DISCUSSION 
  We previously demonstrated that cocaine “opens” the 
BBB constructed with BMVEC’s to HIV-1 entry [2]. In ad-
dition, cocaine induced transcriptional alterations in 
BMVEC’s genes important for cell signaling, cytoskeleton 
organization, cell swelling, vesicular trafficking, and cell 
adhesion, which may lead to acute and long-term changes in 
the properties of the blood-brain barrier. Cocaine induced 
gaps between endothelial cells as early as 30 min after expo-
sure [16]. However, since these effects involved 10
-5 or 10
-6 
M concentrations, some doubt has persisted about the in vivo 
effects of cocaine abuse associated with plasma concentra-
tions below 10
-6 M. Here we show that cocaine concentra-
tions as low as 10
-7 M induce cell signaling in parallel with 
disruption of cell junctions. Cocaine activates mitogen acti-
vated protein kinase (MAPK), protein kinase C (PKC), and 
MLC kinase pathways in BMVEC’s as shown by an increase 
in ERK, MARCKS, and MLC phosphorylation, respectively. 
Paradoxically, the ERK response to cocaine appeared 
stronger at 10
-7 M compared to 10
-6 M cocaine. It has been 
known that cocaine dose response is not always linear. For 
example Carmaci et al. showed that cocaine might manipu-
late the cAMP PKA-Sig-1R and the cAMP-ERK-Sig-1R 
pathways in biphasic fashion [17]. MAPK and PKC path-
ways are critically involved in an increase of endothelial 
paracellular permeability in different types of endothelium 
[18-20]. In addition, cocaine increased MLC phosphoryla-
tion, which initiates EC contraction and leads to gap forma-
tion and permeability increase [18, 21]. The effects of co-
caine appear to be pharmacological, since they are induced 
through a common binding site with benztropine [3]. 
  HIV-1 neurotoxicity is attributed by one school to indi-
rect mechanisms and by another school to direct virus pres-
ence in neurons. The indirect mechanisms, which have been 
more extensively investigated [22], are mediated by macro-
phage products, such as tumor necrosis factor-, platelet-
activating factor, arachidonic acid and its metabolites, nitric 
oxide, quinolinic acid, and glutamate [23-25], and HIV-1 
proteins, such as Tat and gp120, produced by macrophages 
and microglia [26-28]. Human studies of peripheral blood of 
HAD patients noted elevated cytokines and neurotoxins [22], 
and macrophage-specific proteins [29]. However, although 
some investigators still believe that neuronal toxicity is due 
solely to indirect mechanisms [30, 31], neuronal expression 
of  HIV-1  proteins, such as Vpr [32],  and neuronal  presence  
of HIV-1 DNA [33] have been described prior to our study 
and are made plausible by this study. 
   
Fig. (6). (gp120). Immunohistochemical demonstration of HIV-1 antigens in frontal lobe neurons of the patient #5 with HAD (the results of 
staining in patients #1-4 were comparable). (a) Positive neuronal gp120 staining (anti-gp120 (ID6) (brown) and anti-MAP2 (red), 40x). (b) 
Positive gp120 staining of neurons and negative staining of astrocytes (anti-gp120 (ID6) (brown) and anti-GFAP (red), 40x). (c) Positive 
gp120 staining of neurons (anti-gp120 (ID6) absorbed with the negative phage 2.13, 100x). (d) Negative gp120 staining of neurons (anti-
gp120 (ID6) absorbed with the positive phage 3.3, 100x). 30    The Open Virology Journal, 2008, Volume 2  Fiala et al. 
  We have shown (a) absence of robust perivascular 
macrophage infiltration, and (b) presence of HIV-1 antigens, 
gp120, Nef and p24, in neurons of drug using HAD patients. 
Our patients received intensive HAART therapy, which cur-
tailed high-grade HIV-1 viremia suffered by patients in 
1980’s and could have blocked immunological activation 
and brain migration of macrophages [4]. Interestingly, most 
patients with HAD seen at UCLA had a history of cocaine 
abuse, which could be due to the in vivo effects of cocaine 
showed in vitro by this study. The novel immunohistochemi-
cal observations of HIV-1 antigens in neurons of drug abus-
ing HAD patients may be related to the robust effects of co-
caine even at the plasma levels below 10
-6M, which may 
cause subtle breaks of BBB permitting penetration of viral 
proteins or infectious virus into the neuropil and, for un-
known reason, selective invasion of neurons. In this regards, 
it is interesting that in a rat model gp120 is transported into 
cortical neurons by retrograde axonal transport from the 
striatum and hippocampus [34]. 
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